Assessment of remediation Potentials of maize (Zea mays) on sites co-contaminated with Pb and antracene

Phytoremediation is a promising technology for the remediation of sites co-contaminated with inorganic and organic pollutants. A pot experiment was conducted to evaluate the remediation potential of Z.mays in soil co- contaminated with Pb and antracene. Pristine sandy loam soils were polluted with Pb chloride salt and antracene at three different levels (50mg/kg of Pb, 100mg/kg of Pb, and 100mg/kg of Pb+100mg/kg of antracene) and laid out in completely randomized design with 3 replicates. Shoot dry matter weight was significantly reduced (p≤0.05) when compared with control treatments by 40% when exposed to100mg kg-1 of Pb. There was a 48% inhibition of shoot dry matter of Z.mays relative to control treatments when 100 mg Pb kg-1 was mixed with 100 mgkg-1 antracene. Root and shoot metal concentration in Zea mays increased with increasing concentration of Pb. The average Translocation Factor (TF < 1 (0.69) obtained suggests that Zea mays predominantly retains Pb in the root portion of the plant. There was a 5% increase in shoot Pb concentration when soil was contaminated with Pb and antracene. The extractable antracene decreased significantly (p≤0.05) in soil planted with Z.mays as well as in pots without maize plant. This accounted for 65 and 72% of antracene dissipation in planted soil and 40-46% dissipation in unplanted soil. This result suggested that Zeamays is a promising candidate for uptake Pb and dissipation of antracene in co-contaminated soils

US Cosmic Visions: New Ideas in Dark Matter 2017: Community Report

This white paper summarizes the workshop "U.S. Cosmic Visions: New Ideas in Dark Matter" held at University of Maryland on March 23-25, 2017.Comment: 102 pages + reference

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. METHODS AND RESULTS: GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death. CONCLUSION: The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Management Leadership Styles and Profitability of Production Firms in South East, Nigeria

&lt;p&gt;&lt;i&gt;The study examined the relationship between management leadership styles and profitability of production firms in South East, Nigeria. The specific objectives include to examine the extent of which autocratic leadership relates to profitability of production firms in South East, Nigeria and to investigate the extent of which democratic leadership relates to profitability of production firms in South East, Nigeria. The study adopted survey research design. The sample size of the study was 132 using purposive statistical method under what previous authors did. Questionnaire instrument was validated. The findings revealed that autocratic leadership had significant positive relationship with profitability of production firms in South East, Nigeria (t=.034, pv=0.05&lt;0.000) and democratic leadership had significant positive relationship with profitability of production firms in South East, Nigeria (t=.049, pv=0.05&lt;0.000). Based on findings, we conclude that conclude that management leadership styles had significant positive relationship with profitability of production firms in South East, Nigeria. Based on findings, the study recommended that government should put adequate leadership training, workshop and seminars to enable production boost their workers intellectual ability.&lt;/i&gt;&lt;/p&gt

Validation of antihypertensive drug requirement to measure the severity of hypertension and the efficacy of lifestyle intervention

Background/objective: The ongoing pandemic of non-communicable diseases, with systemic arterial hypertension at the forefront, mandates urgent attention to the aetiopathogenic mechanism rather than continuing to rely on suppressive drug therapies. Lifestyle interventions (such as diet, sleep and exercise) may have substantial impact on blood pressure control in hypertension. However this may not be evident in clinical trials of lifestyle intervention if the blood pressure was previously controlled by drugs. We therefore sought to develop an alternative method of measuring the impact of lifestyle intervention, rather than rely on blood pressure measurement alone. Methods: The open trial of a personalized food avoidance dietary approach to stop hypertension was approved by the UNTH ethics committee. The Antihypertensive Drug Treatment Requirement (ADTR) score was calculated as the total number of defined unitary dosages of antihypertensive drugs times adherence +/- 0.1 accordingly for each mm Hg that average systolic pressure either exceeds 120 mm Hg (AOBP or home BP, whichever higher) or goes below 100 mm Hg Hg (AOBP or home BP, whichever lower). The dietary compliance score was based on the frequency of major/ minor dietary indiscretion (as per the PFADASH guidelines) i.e. less than (= GOOD) or more than (= POOR) once a month/ once a fortnight, respectively. Normality of data distribution was assessed by computing Shapiro-Wilk statistics. Cronbach's alpha reliability coefficient was used to assess internal consistency of ADTR measurements. Results: Bi-quarterly Shapiro – Wilk statistics for AdhRx scores and ADTR scores showed more than 80% likelihood of being normally distributed at 5% significance level (i.e. 13 out of 16 data sets tested). Cronbach's alpha reliability coefficient was 0.980. This confirmed consistency of the ADTR measurement scale. For three study participants who improved to Good compliance (after dietary counseling) and four participants who failed to improve, Good compliance was associated with lower ADTR scores, but the differences between Good (mean ADTR of 1.07+0.82) and Poor (3.81+3.15) were not statistically significant (p = 0.210). For the three study participants who transited from Poor to Good compliance (in response to counseling), there was a high degree of negative correlation (i.e. decline of drug requirement) which was statistically significant in two of them (p&lt;0.05). However, in the study participants who failed to improve their dietary compliance, there was a relative lack of correlation (with higher p values). The overall pattern is consistent with a negative association between dietary compliance and ADTR score. Conclusion: We conclude that ADTR scores are useful and valid tools to assess the impact of dietary interventions which address the aetiopathogenic mechanism in essential hypertension. This enables differentiation between blood pressure lowering by drugs and that due to dietary intervention

Efficacy of zinc supplementation for the treatment of dysmenorrhoea: a double-blind randomised controlled trial

Objectives To determine the efficacy of zinc sulfate supplementation in managing dysmenorrhoea. Methods In total, 103 high school students were randomised into an experimental arm (52 students) and a control arm (51 students) and received 40-mg zinc sulfate or placebo, respectively, over three cycles. Primary outcome measures were the mean Visual Analogue Scale score, which measured pain over three cycles, and the frequency of nausea and vomiting. Secondary outcomes were the use of additional analgesics and the frequency of allergic reactions. Results Fifty participants were analysed in each group. Mean pain scores were not significantly different between the groups before administering zinc sulfate therapy. Following the intervention, the mean pain scores for the treatment (2.80 ± 2.28) and placebo (3.48 ± 2.85) groups were not significantly different in the first cycle; however, scores in the treatment group were significantly better in the second (2.56 ± 1.97 vs 3.80 ± 2.77) and third (1.95 ± 1.72 vs 3.95 ± 2.82) cycles. No significant differences were observed between the groups in the nausea and vomiting incidence and the requirement for additional analgesics. Conclusions Zinc sulfate reduces dysmenorrhoea severity with minimal or no adverse effects, especially with more than one cycle of usage. Trial Registration Number: PACTR202105843292338. The trial is publicly available and was registered at www.pactr.org on 25 May 2021